FLC Capital Advisors Has $252,000 Position in Novartis AG (NYSE:NVS)

FLC Capital Advisors increased its position in shares of Novartis AG (NYSE:NVS) by 9.3% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 2,586 shares of the company’s stock after buying an additional 220 shares during the quarter. FLC Capital Advisors’ holdings in Novartis were worth $252,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of NVS. Legacy Investment Solutions LLC acquired a new stake in shares of Novartis in the third quarter valued at approximately $28,000. Fortitude Family Office LLC grew its position in Novartis by 503.8% in the third quarter. Fortitude Family Office LLC now owns 320 shares of the company’s stock valued at $37,000 after purchasing an additional 267 shares in the last quarter. Clean Yield Group acquired a new stake in Novartis in the 3rd quarter valued at $43,000. Brooklyn Investment Group bought a new stake in Novartis during the 4th quarter worth about $55,000. Finally, Beaird Harris Wealth Management LLC boosted its stake in shares of Novartis by 280.5% during the 3rd quarter. Beaird Harris Wealth Management LLC now owns 704 shares of the company’s stock worth $81,000 after buying an additional 519 shares during the last quarter. Institutional investors and hedge funds own 13.12% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the company. HSBC downgraded Novartis from a “hold” rating to a “reduce” rating in a research report on Wednesday, December 4th. Erste Group Bank reiterated a “hold” rating on shares of Novartis in a research note on Tuesday, November 19th. Finally, BMO Capital Markets raised their target price on shares of Novartis from $118.00 to $120.00 and gave the company a “market perform” rating in a research note on Wednesday, October 30th. Two equities research analysts have rated the stock with a sell rating and seven have given a hold rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $121.50.

Novartis Stock Performance

NVS opened at $97.51 on Monday. The company has a quick ratio of 0.90, a current ratio of 1.11 and a debt-to-equity ratio of 0.55. The stock has a market cap of $199.30 billion, a price-to-earnings ratio of 11.32, a PEG ratio of 1.36 and a beta of 0.57. Novartis AG has a 12-month low of $92.35 and a 12-month high of $120.92. The business has a 50 day moving average of $100.61 and a 200-day moving average of $109.01.

Novartis (NYSE:NVS) last announced its quarterly earnings results on Tuesday, October 29th. The company reported $2.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.94 by $0.12. The business had revenue of $12.82 billion during the quarter, compared to the consensus estimate of $12.62 billion. Novartis had a return on equity of 34.80% and a net margin of 35.96%. During the same quarter last year, the firm posted $1.74 EPS. On average, equities research analysts expect that Novartis AG will post 7.63 earnings per share for the current year.

About Novartis

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.